- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
The AGO-OVAR 12 / LUME-Ovar 1 study is a Phase III multicentre, double-blind, randomised trial to investigate the efficacy and safety of BIBF 1120* in combination with carboplatin and paclitaxel compared with placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer. Please look at the infographic for more information.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
